Director of Thought Leader Development

Director of Thought Leader Development About the Company Join an innovative biopharmaceutical company committed to making a difference in the field of medicine. Industry Pharmaceuticals Type Public Company Founded 2015 Employees 51-200 Categories Pharmaceuticals Medicine Manufacturing Chemical Products Specialties Medicinal chemistry Hereditary angioedema Drug discovery Drug development Biotechnology Pharmaceuticals About the Role The company is seeking a dynamic Director of Thought Leader Development. You will lead a dedicated team focused on establishing and nurturing relationships with key influencers and decision-makers in the hereditary angioedema (HAE) community. Your responsibilities will include strategic operational planning to position the company as a trusted partner among thought leaders, collaborating with various departments to meet customer needs, and overseeing insight reporting at multiple levels. In this role, you will manage a talented team, promote effective collaboration, and ensure compliance with medical and commercial guidelines. A Bachelor's degree is required (advanced degree preferred), along with a minimum of 15 years of commercial experience in the biotech or pharma sectors, including 5 years in thought leadership development or liaison management. You should possess a proven track record in launch planning and execution, particularly within rare disease, immunology, or specialty markets. Key qualifications include: Extensive experience in insight generation and customer segmentation to inform brand strategies. Proven ability to lead high-performance commercial teams. Exceptional communication skills with a talent for influencing senior stakeholders. A genuine passion for enhancing the lives of patients with rare diseases. A patient-first mindset coupled with strategic, big-picture thinking and a competitive drive for results. Hiring Manager Title General Manager, Head of Commercial Travel Percent Less than 10% Functions Product Marketing

Created: 2026-03-10